Neuropace Inc.

03/31/2021 | Press release | Archived content

NeuroPace Receives FDA Breakthrough Device Designation for RNS System for Idiopathic Generalized Epilepsy

Neuropace Inc. published this content on March 31, 2021, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 17, 2025 at 10:27 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]